Susan L Kalled
Susan L Kalled
Autoimmunity results from a break in self-tolerance involving humoral and/or cell-mediated immune mechanisms. One pathological consequence of a failure in central and/or peripheral tolerance is the generation of autoantibodies and subsequen...
Regenerative medicine through mesenchymal stem cells for bone and cartilage repair [0.03%]
通过间充质干细胞的再生医学实现骨和软骨修复
Danièle Noël,Farida Djouad,Christian Jorgense
Danièle Noël
Bone and cartilage defects are common features of bone fracture and joint diseases, such as rheumatoid arthritis or osteoarthritis, that have great social and economic impact on the aging occidental population. Despite progress in orthopedi...
Yoon S Cho-Chung
Yoon S Cho-Chung
Progress in antisense technology has been rapid, and the traditional antisense inhibition of gene expression has now been viewed at a genomic scale. This global view has led to a deeper understanding of the mechanism of action, the eliminat...
Joanna B Opalinska,Alan M Gewirtz
Joanna B Opalinska
Repinotan Bayer [0.03%]
Repinotan拜耳公司研发
Helmi L Lutsep
Helmi L Lutsep
Bayer is developing the aminomethylchroman derivative, repinotan, a 5-HT1A agonist, as a potential treatment for ischemic stroke and traumatic brain injury [216172]. It has completed phase III trials in Canada and the US [342562], [344747]....
DP-VPA D-Pharm [0.03%]
DP-VPA D药学专业
David M Labiner
David M Labiner
Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression a...
Christine E Heading
Christine E Heading
Conus peptides comprise a diverse class of bioactive molecules, each of which is believed to have a biological target. From the 50,000 plus molecules thought to exist, several groups are judged to have potential neuroprotective activity. Th...
Cynthia Darlington
Cynthia Darlington
Valery Feigin
Valery Feigin
The oxazole derivative, irampanel, a non-competitive AMPA receptor antagonist, is under development by Boehringer Ingelheim for the potential treatment of stroke [329079]. Phase I/IIa trials for stroke had been initiated by July 2000 [37414...
Dennis Mungall
Dennis Mungall
BIBR-1048, a thrombin inhibitor and an orally-active prodrug of BIBR-953ZW, is under development by Boehringer Ingelheim as a potential antithrombotic agent [331881]. By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism an...